Amoeba : With 8 partnerships in biocontrol, Amoéba confirms a new development phase

PRESS RELEASE

WITH 8 RESEARCH PARTNERSHIPS IN BIOCONTROL,

AMOEBA CONFIRMS A NEW DEVELOPMENT PHASE

Chassieu (France), april 29, 2020 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, unveils its strategic ambitions for its biocontrol activity and specifies the future key stages of its new development phase.

A new phase of large-scalemulti-partner tests

The results published by Amoeba in July 2019, demonstrating the amoeba lysate efficacy against vine downy mildew, potato late blight and bean rust, have raised the interest of many players in the agrochemical and biosolutions industries, who have expressed the will to carry out their own in-house tests.

Thus, eight candidates have signed Material Transfer Agreements (MTA) with Amoéba. The purpose of these research partnerships for Amoéba consists in providing experimental products (in various formulations) containing the amoeba lysate Willaertia magna C2c Maky. In return, the eight agrochemical groups will finance and carry out their own field tests across Europe to assess the products performance in preventing diseases on different crops.

A data multiplication and a move forward on future steps to generate early revenues.

At the end of this testing period, which runs from spring to early autumn 2020, the candidates will send Amoeba their results. If tests are successful, further negotiations should take place between Amoeba and the various stakeholders to define possible milestone payments and the basis for future business relations. Three or four partners should be selected to move to the next product development and commercialization phase.

An upgrade of the regulatory dossier by own and partnership tests

Amoeba will continue its own field tests in different market segments: specialty crops (vine, tomato, vegetable crops) and field crops (cereals, soybean, beet, potato). The targeted diseases (mildew, rust, septoria, fusarium and cercosporia) are among those that cause significant yield reductions for farmers.

This new evaluation phase for 2020, in the field or in climatic chambers, on its own or in partnership, carried out on 3 continents and 11 countries, will represent a total of more than 145 tests, among which 75 for the company. Results obtained will complete and enrich the regulatory dossier, which continues to be filed by Amoéba.

1

Amoéba arranges for obtaining the substance approval with the submission of the regulatory dossiers by the end of May in Europe and July in the United States. The partners will then take charge of the marketing authorizations (MA). The first marketing authorizations could be issued in 2022 in the United States and 2024 in Europe.

A validated financing and a continuation of activity despite the current sanitary crisis

The tests, carried out by Amoeba, are financed through the new OCA (convertible bond) issue contract with Nice & Green of €6.240 million. Intended to ensure the continuity of operations until August 2021, this financing gives to Amoeba the necessary means to continue its activity, particularly in terms of regulatory files (biocontrol and biocide) and R&D until the first commercial revenues.

Ten years ago, Amoeba was born from the discovery of the unique properties of the amoeba Willaertia magna C2c Maky. Driven by a desire to offer alternative solutions to all-chemicals, we developed our lysate for application in biocontrol. The first tests, in climatic chambers and in the field, validated our research and development efforts. The strategy implemented over the past year to extend research to third-party partnerships has been successful: no less than 8 agreements have just been signed with key players in the agrochemical industry. This new phase of strategic development in biocontrol enables us to both enrich our biocontrol regulatory dossiers to be filed in Europe and the United States and prepare for the marketing of biosolutions worldwide. These decisive progresses in biocontrol do not prevent us from advancing in parallel in the processing of our biocidal dossier which still keeps its full potential. explains Fabrice Plasson, Chairman and CEO of Amoéba

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1)on a global chemical biocide market for water treatment, evaluated at €21Bn (2)and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3)in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:
Amoéba	Investors and Media Relations
Valérie FILIATRE	Grégory BOSSON / Mathieu CALLEUX
General Manager	Agence Calyptus
[phone]	[phone]

2

[e-mail]

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 25, 2019 under number D19-0383 and the prospectus approved by the AMF on january 16, 2020 under number 20-011 (a copy of which is available on www.amoeba-biocide.com).The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.

3